| Literature DB >> 11895764 |
Eric Oksenhendler1, Emmanuelle Boulanger, Lionel Galicier, Ming-Qing Du, Nicolas Dupin, Tim C Diss, Rifat Hamoudi, Marie-Thérèse Daniel, Félix Agbalika, Chris Boshoff, Jean-Pierre Clauvel, Peter G Isaacson, Véronique Meignin.
Abstract
Multicentric Castleman disease (MCD) is a distinct type of lymphoproliferative disorder associated with inflammatory symptoms and interleukin 6 (IL-6) dysregulation. In the context of human immunodeficiency virus (HIV) infection, MCD is associated with Kaposi sarcoma-associated herpesvirus, also called human herpesvirus type 8 (KSHV/HHV8). Within a prospective cohort study on 60 HIV-infected patients with MCD, and a median follow-up period of 20 months, 14 patients developed KSHV/HHV8-associated non-Hodgkin lymphoma (NHL): 3 "classic" KSHV/HHV8(+) Epstein-Barr virus-positive (EBV(+)) primary effusion lymphoma (PEL), 5 KSHV/HHV8(+) EBV(-) visceral large cell NHL with a PEL-like phenotype, and 6 plasmablastic lymphoma/leukemia (3/3 KSHV/HHV8(+) EBV(-)). The NHL incidence observed in this cohort study (101/1000 patient-years) is about 15-fold what is expected in the general HIV(+) population. MCD-associated KSHV/HHV8(+) NHL fell into 2 groups, suggesting different pathogenesis. The plasmablastic NHL likely represents the expansion of plasmablastic microlymphoma from the MCD lesion and progression toward aggressive NHL. In contrast, the PEL and PEL-like NHL may implicate a different original infected cell whose growth is promoted by the cytokine-rich environment of the MCD lesions.Entities:
Mesh:
Substances:
Year: 2002 PMID: 11895764 DOI: 10.1182/blood.v99.7.2331
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113